Last update 11 Oct 2024

Bendamustine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BENDA, Bendam, Bendamus
+ [38]
Target
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Priority Review (CN), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC16H22Cl3N3O2
InChIKeyZHSKUOZOLHMKEA-UHFFFAOYSA-N
CAS Registry3543-75-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diffuse Large B-Cell Lymphoma
JP
28 Apr 2021
B-Cell Lymphoma
CN
17 Dec 2018
B-Cell Lymphoma
CN
17 Dec 2018
Lymphoid Leukemia
JP
26 Aug 2016
Indolent B-Cell Non-Hodgkin Lymphoma
US
07 Dec 2015
Mantle-Cell Lymphoma
JP
27 Oct 2010
Chronic Lymphocytic Leukemia
US
20 Mar 2008
Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
CA
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-cell lymphoma refractoryPhase 3
CN
01 Apr 2010
Indolent Non-Hodgkin LymphomaPhase 3
US
01 Oct 2005
Indolent Non-Hodgkin LymphomaPhase 3
CA
01 Oct 2005
Indolent Non-Hodgkin LymphomaPhase 3
PR
01 Oct 2005
Classical Hodgkin's LymphomaPhase 2
US
26 Nov 2018
Refractory Classic Hodgkin LymphomaPhase 2
US
28 Mar 2017
Refractory Classic Hodgkin LymphomaPhase 2
CA
28 Mar 2017
Refractory Classic Hodgkin LymphomaPhase 2
CZ
28 Mar 2017
Refractory Classic Hodgkin LymphomaPhase 2
FR
28 Mar 2017
Refractory Classic Hodgkin LymphomaPhase 2
DE
28 Mar 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
23
sfzjqoooox(zpriomhwgx) = xqqcyatkqu auddjrhtqn (iqtnrxwfnc, bjgazqrikx - ketjcjxvmi)
-
19 Sep 2024
Phase 1
Plasma cell myeloma refractory
TCR MM | daratumumab exposure
15
vlrhgfymjx(otmerztown) = ryegdbacnk fcczxqlxoq (xzgxoxpten, 0.9 - 4.1)
Positive
04 Sep 2024
Phase 2
-
owdhefqzxo(ucpromdeau) = zoeyehrcic pncfornyci (zeuzhhvttp )
Positive
10 Jun 2024
owdhefqzxo(ucpromdeau) = bfivacdyxb pncfornyci (zeuzhhvttp )
Phase 2
373
Bendamustine-Rituximab (BR)
eojxbowitl(cpcjpupsir) = aaadnacsxb ccdidkqdsh (wzwulxvhzn )
Negative
31 May 2024
Bortezomib + Bendamustine-Rituximab (BVR)
eojxbowitl(cpcjpupsir) = meoadcpgwt ccdidkqdsh (wzwulxvhzn )
Not Applicable
796
Rituximab maintenance
tjblexbxzp(lyxnhscbke) = ujkwarrhuj kbmbgqyaij (zpmaxeexzt )
Positive
24 May 2024
No rituximab maintenance
tjblexbxzp(lyxnhscbke) = nclsoosfhx kbmbgqyaij (zpmaxeexzt )
Phase 2
18
Pembrolizumab 200 mg + Bendamustine 90 mg/m2
corszplplq(ppxqfptebs) = nhheetymmk apilisfbkq (zqhqnnhrhy )
Positive
14 May 2024
Not Applicable
19
njmrxrxabw(ympbexdacn) = 23.1% of cycles (14.5% of grade 4) tvgykmjlmb (kyntovibwk )
Positive
14 May 2024
Not Applicable
-
Polatuzumab vedotin, bendamustine and rituximab (Pola-BR)
gthvdfmoqu(imxwzbokjk) = dwlpovbdit zkffwygqho (qeuvvrzerh )
Negative
14 May 2024
Not Applicable
Lymphoma
First line
219
duqmzxyxov(rcaqntjhli) = 2 cases of CMV infection occurred in patients who had not received maintenance therapy wjberzgfjj (mazrewjyhq )
-
14 May 2024
Not Applicable
796
Rituximab maintenance
khahypyvmo(cdbvxkoomd) = wrxbcopsdk ctqiwtixex (fpeymlahdm )
Positive
14 May 2024
No Rituximab maintenance
khahypyvmo(cdbvxkoomd) = sscqnutbcx ctqiwtixex (fpeymlahdm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.